What is Cogent Biosciences Forward Dividend Yield %?
As of today (2024-04-28), the Forward Annual Dividend Yield of Cogent Biosciences is 0.00%.
As of today (2024-04-28), the Trailing Annual Dividend Yield of Cogent Biosciences is 0.00%.
COGT's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.56 * Ranked among companies with meaningful Forward Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Competitive Comparison of Cogent Biosciences's Forward Dividend Yield %
For the Biotechnology subindustry, Cogent Biosciences's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cogent Biosciences's Forward Dividend Yield % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cogent Biosciences's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Cogent Biosciences's Forward Dividend Yield % falls into.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Cogent Biosciences Forward Dividend Yield % Related Terms
Thank you for viewing the detailed overview of Cogent Biosciences's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Cogent Biosciences (Cogent Biosciences) Business Description
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
COGT has been successfully added to your